Edward J. Hartsough

发表

The next‐generation BET inhibitor, PLX51107, delays melanoma growth in a CD8‐mediated manner

A. Aplin, A. Berger, I. Chervoneva, 2019, Pigment cell & melanoma research.

Beneficial Effects of RAF Inhibitor in Mutant BRAF Splice Variant–Expressing Melanoma

A. Aplin, Edward J. Hartsough, Kevin J. Basile, 2014, Molecular Cancer Research.

Lysine Methylation Promotes VEGFR-2 Activation and Angiogenesis

N. Rahimi, J. Weinberg, Yan Jiang, 2013, Science Signaling.

Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis.

E. Alnemri, U. Rodeck, A. Aplin, 2019, Cancer discovery.

PRMT4-mediated arginine methylation promotes tyrosine phosphorylation of VEGFR-2 and regulates filopodia protrusions

N. Rahimi, Razie Amraei, Edward J. Hartsough, 2022, iScience.

Cell Adhesion Molecules in Plasticity and Metastasis

Edward J. Hartsough, J. A. Smart, Julia Oleksak, 2020, Molecular Cancer Research.

Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor.

A. Aplin, Y. Setiady, C. Kugel, 2014, Cancer research.

CADM1 is a TWIST1-regulated suppressor of invasion and survival

A. Aplin, I. Chervoneva, C. Kugel, 2019, Cell Death & Disease.

Inhibition of mutant BRAF splice variant signaling by next‐generation, selective RAF inhibitors

Kaitlyn Le, A. Aplin, Edward J. Hartsough, 2014, Pigment cell & melanoma research.

Therapeutics , Targets , and Chemical Biology Function-Blocking ERBB 3 Antibody Inhibits the Adaptive Response to RAF Inhibitor

A. Aplin, Y. Setiady, C. Kugel, 2014 .

Resistance to RAF inhibitors revisited

A. Aplin, Edward J. Hartsough, Y. Shao, 2013, The Journal of investigative dermatology.

Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo

A. Aplin, G. Bollag, K. Knudsen, 2017, Molecular Cancer Therapeutics.

In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors.

P. Fortina, A. Aplin, Edward J. Hartsough, 2013, Cancer research.

BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association.

Kaitlyn Le, A. Aplin, Edward J. Hartsough, 2018, Cell reports.

RNF121 Inhibits Angiogenic Growth Factor Signaling by Restricting Cell Surface Expression of VEGFR‐2

N. Rahimi, J. Pudney, Rosana D. Meyer, 2016, Traffic.

Identification of IGPR-1 as a novel adhesion molecule involved in angiogenesis

N. Rahimi, Rosana D. Meyer, Edward J. Hartsough, 2012, Molecular biology of the cell.

Hypoxia-induced expression of phosducin-like 3 regulates expression of VEGFR-2 and promotes angiogenesis

Lois E. H. Smith, N. Rahimi, Yan Jiang, 2015, Angiogenesis.

A STATement on Vemurafenib-Resistant Melanoma

A. Aplin, Edward J. Hartsough, 2013, The Journal of investigative dermatology.

An Ex Vivo Brain Slice Model to Study and Target Breast Cancer Brain Metastatic Tumor Growth.

N. Simone, M. Reginato, R. Moeller, 2021, Journal of visualized experiments : JoVE.

TMIGD1 is a novel adhesion molecule that protects epithelial cells from oxidative cell injury.

N. Rahimi, J. Henderson, Rosana D. Meyer, 2015, The American journal of pathology.

Of Mice and Melanoma: PDX System for Modeling Personalized Medicine

A. Aplin, Edward J. Hartsough, 2016, Clinical Cancer Research.

Multi-omics profiling shows BAP1 loss is associated with upregulated cell adhesion molecules in uveal melanoma.

A. Aplin, J. Harbour, Vivian Chua, 2022, Molecular cancer research : MCR.

Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor.

A. Aplin, Y. Setiady, C. Kugel, 2014, Cancer research.

Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma

A. Aplin, Edward J. Hartsough, M. Daniali, 2024, Cell death discovery.